Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Oscar Gary Bukstein, M.D.

Title
Institution
Department
Address
Phone

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01MH077676 (MOLINA, BROOKE S.G.) Aug 15, 2008 - Jun 30, 2013
    NIH/NIMH
    2/4-Stimulant and Risperidone for Youth with Severe Physical Aggression
    Role: Co-Principal Investigator
  2. R21DA016631 (BUKSTEIN, OSCAR G) Sep 1, 2003 - Jun 30, 2008
    NIH/NIDA
    Home Base Treatment for Drug Use in Early Adolescents
    Role: Principal Investigator
  3. U10MH066775 (BUKSTEIN, OSCAR G) Sep 6, 2002 - Jul 31, 2007
    NIH/NIMH
    RUPP-PI
    Role: Principal Investigator
  4. K24AA000301 (BUKSTEIN, OSCAR G) Sep 30, 2001 - Aug 31, 2007
    NIH/NIAAA
    PSYCHOPHARMACOLOGY OF ADOLESCENTS WITH AUD AND ADHD
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Walter HJ, Bukstein OG, Abright AR, Keable H, Ramtekkar U, Ripperger-Suhler J, Rockhill C. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. J Am Acad Child Adolesc Psychiatry. 2020 May 18. PMID: 32439401.
    Citations:    
  2. Johnstone JM, Leung BMY, Srikanth P, Hatsu I, Perez L, Gracious B, Tost G, Aman MG, Gadow KD, Findling RL, Bukstein O, Arnold LE. Development of a Composite Primary Outcome Score for Children with Attention-Deficit/Hyperactivity Disorder and Emotional Dysregulation. J Child Adolesc Psychopharmacol. 2020 Apr; 30(3):166-172. PMID: 32101469.
    Citations:    
  3. Reus VI, Fochtmann LJ, Bukstein O, Eyler AE, Hilty DM, Horvitz-Lennon M, Mahoney J, Pasic J, Weaver M, Wills CD, McIntyre J, Kidd J, Yager J, Hong SH. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Focus (Am Psychiatr Publ). 2019 Apr; 17(2):158-162. PMID: 32021585.
    Citations:    
  4. Reus VI, Fochtmann LJ, Bukstein O, Eyler AE, Hilty DM, Horvitz-Lennon M, Mahoney J, Pasic J, Weaver M, Wills CD, McIntyre J, Kidd J, Yager J, Hong SH. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry. 2018 01 01; 175(1):86-90. PMID: 29301420.
    Citations: 3     Fields:    Translation:Humans
  5. Barterian JA, Arnold LE, Brown NV, Farmer CA, Williams C, Findling RL, Kolko DJ, Bukstein OG, Molina BSG, Townsend L, Aman MG. Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings. J Am Acad Child Adolesc Psychiatry. 2017 Dec; 56(12):1026-1033. PMID: 29173736.
    Citations:    Fields:    Translation:Humans
  6. Walter HJ, Bukstein OG. Forward to the Future: Clinical Updates and Clinical Practice Guidelines. J Am Acad Child Adolesc Psychiatry. 2017 10; 56(10):811-812. PMID: 28942802.
    Citations:    Fields:    
  7. Bukstein OG. Challenges and Gaps in Understanding Substance Use Problems in Transitional Age Youth. Child Adolesc Psychiatr Clin N Am. 2017 04; 26(2):253-269. PMID: 28314454.
    Citations:    Fields:    Translation:Humans
  8. Tamm L, Denton CA, Epstein JN, Schatschneider C, Taylor H, Arnold LE, Bukstein O, Anixt J, Koshy A, Newman NC, Maltinsky J, Brinson P, Loren REA, Prasad MR, Ewing-Cobbs L, Vaughn A. Comparing treatments for children with ADHD and word reading difficulties: A randomized clinical trial. J Consult Clin Psychol. 2017 May; 85(5):434-446. PMID: 28333510.
    Citations: 2     Fields:    Translation:Humans
  9. Findling RL, Townsend L, Brown NV, Arnold LE, Gadow KD, Kolko DJ, McNamara NK, Gary DS, Kaplin DB, Farmer CA, Kipp H, Williams C, Butter EM, Bukstein OG, Rice R, Buchan-Page K, Molina BS, Aman MG. The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders. J Child Adolesc Psychopharmacol. 2017 02; 27(1):52-65. PMID: 28212067.
    Citations: 1     Fields:    Translation:Humans
  10. Pelham WE, Smith BH, Evans SW, Bukstein O, Gnagy EM, Greiner AR, Sibley MH. The Effectiveness of Short- and Long-Acting Stimulant Medications for Adolescents With ADHD in a Naturalistic Secondary School Setting. J Atten Disord. 2017 01; 21(1):40-45. PMID: 23460704.
    Citations: 4     Fields:    Translation:Humans
  11. Pelham WE, Meichenbaum DL, Smith BH, Sibley MH, Gnagy EM, Bukstein O. Acute Effects of MPH on the Parent-Teen Interactions of Adolescents With ADHD. J Atten Disord. 2017 01; 21(2):158-167. PMID: 23543401.
    Citations: 1     Fields:    Translation:Humans
  12. Pelham WE, Gnagy EM, Sibley MH, Kipp HL, Smith BH, Evans SW, Bukstein O. Attributions and Perception of Methylphenidate Effects in Adolescents With ADHD. J Atten Disord. 2017 01; 21(2):129-136. PMID: 23893533.
    Citations: 2     Fields:    Translation:Humans
  13. Farmer CA, Epstein JN, Findling RL, Gadow KD, Arnold LE, Kipp H, Kolko DJ, Butter E, Schneider J, Bukstein OG, McNamara NK, Molina BS, Aman MG. Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory. J Child Adolesc Psychopharmacol. 2017 03; 27(2):117-124. PMID: 27348211.
    Citations:    Fields:    Translation:Humans
  14. Gadow KD, Brown NV, Arnold LE, Buchan-Page KA, Bukstein OG, Butter E, Farmer CA, Findling RL, Kolko DJ, Molina BS, Rice RR, Schneider J, Aman MG. Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial. J Am Acad Child Adolesc Psychiatry. 2016 06; 55(6):469-78. PMID: 27238065.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  15. Bukstein OG. Substance Use Disorders Among Adolescents. Focus (Am Psychiatr Publ). 2016 Jan; 14(1):57-59. PMID: 31975795.
    Citations:    
  16. Arnold LE, Gadow KD, Farmer CA, Findling RL, Bukstein O, Molina BS, Brown NV, Li X, Rundberg-Rivera EV, Bangalore S, Buchan-Page K, Hurt EA, Rice R, McNamara NK, Aman MG. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. J Child Adolesc Psychopharmacol. 2015 Apr; 25(3):203-12. PMID: 25885010.
    Citations: 4     Fields:    Translation:Humans
  17. Farmer CA, Brown NV, Gadow KD, Arnold LE, Kolko DG, Findling RL, Molina BS, Buchan-Page KA, Rice RR, Bangalore SS, Bukstein O, Rundberg-Rivera EV, McNamara N, Aman MG. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2015 Apr; 25(3):213-24. PMID: 25885011.
    Citations: 4     Fields:    Translation:Humans
  18. Rundberg-Rivera EV, Townsend LD, Schneider J, Farmer CA, Molina BB, Findling RL, Gadow KD, Bukstein OG, Arnold LE, Kolko DJ, Buchan-Page KA, McNamara NK, Michel C, Austin A, Kipp H, Rice RR, Aman MG. Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression. J Child Adolesc Psychopharmacol. 2015 Apr; 25(3):225-33. PMID: 25885012.
    Citations: 2     Fields:    Translation:Humans
  19. Kaat A, Farmer C, Gadow K, Findling RL, Bukstein O, Arnold LE, Bangalore S, McNamara N, Aman M. Factor Validity of a Proactive and Reactive Aggression Rating Scale. J Child Fam Stud. 2015 Sep 01; 24(9):2734-2744. PMID: 26504369.
    Citations: 1     
  20. Cutler AJ, Brams M, Bukstein O, Mattingly G, McBurnett K, White C, Rubin J. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2014 Oct; 53(10):1092-101. PMID: 25245353.
    Citations: 4     Fields:    Translation:Humans
  21. Gadow KD, Arnold LE, Molina BS, Findling RL, Bukstein OG, Brown NV, McNamara NK, Rundberg-Rivera EV, Li X, Kipp HL, Schneider J, Farmer CA, Baker JL, Sprafkin J, Rice RR, Bangalore SS, Butter EM, Buchan-Page KA, Hurt EA, Austin AB, Grondhuis SN, Aman MG. Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. J Am Acad Child Adolesc Psychiatry. 2014 Sep; 53(9):948-959.e1. PMID: 25151418.
    Citations: 15     Fields:    Translation:Humans
  22. Goldstein BI, Goldstein TR, Collinger KA, Axelson DA, Bukstein OG, Birmaher B, Miklowitz DJ. Treatment development and feasibility study of family-focused treatment for adolescents with bipolar disorder and comorbid substance use disorders. J Psychiatr Pract. 2014 May; 20(3):237-48. PMID: 24847999.
    Citations: 5     Fields:    Translation:Humans
  23. Kolko DJ, Lindhiem O, Hart J, Bukstein OG. Evaluation of a booster intervention three years after acute treatment for early-onset disruptive behavior disorders. J Abnorm Child Psychol. 2014; 42(3):383-98. PMID: 23494526.
    Citations: 4     Fields:    Translation:Humans
  24. Aman MG, Bukstein OG, Gadow KD, Arnold LE, Molina BS, McNamara NK, Rundberg-Rivera EV, Li X, Kipp H, Schneider J, Butter EM, Baker J, Sprafkin J, Rice RR, Bangalore SS, Farmer CA, Austin AB, Buchan-Page KA, Brown NV, Hurt EA, Grondhuis SN, Findling RL. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 2014 Jan; 53(1):47-60.e1. PMID: 24342385.
    Citations: 27     Fields:    Translation:Humans
  25. Bukstein OG. Personality-targeted interventions delivered by teachers may be effective at reducing alcohol use. Evid Based Ment Health. 2013 Nov; 16(4):100. PMID: 23863970.
    Citations: 1     Fields:    Translation:Humans
  26. Pearson DA, Santos CW, Aman MG, Arnold LE, Casat CD, Mansour R, Lane DM, Loveland KA, Bukstein OG, Jerger SW, Factor P, Vanwoerden S, Perez E, Cleveland LA. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. J Child Adolesc Psychopharmacol. 2013 Jun; 23(5):337-51. PMID: 23782128.
    Citations: 9     Fields:    Translation:Humans
  27. Bukstein OG, Head J. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder. Expert Opin Pharmacother. 2012 Oct; 13(15):2207-13. PMID: 22957772.
    Citations: 6     Fields:    Translation:Humans
  28. Bukstein OG. Taking note of over-the-counter remedies for adolescents with cannabis dependence. Am J Psychiatry. 2012 Aug; 169(8):771-3. PMID: 22854924.
    Citations:    Fields:    Translation:Humans
  29. Bukstein OG. Attention deficit hyperactivity disorder and substance use disorders. Curr Top Behav Neurosci. 2012; 9:145-72. PMID: 21789746.
    Citations: 2     Fields:    Translation:Humans
  30. Shenk CE, Dorn LD, Kolko DJ, Susman EJ, Noll JG, Bukstein OG. Predicting Treatment Response for Oppositional Defiant and Conduct Disorder Using Pre-treatment Adrenal and Gonadal Hormones. J Child Fam Stud. 2012 Dec; 21(6):973-981. PMID: 27429540.
    Citations:    
  31. Kraus LJ, Thomas CR, Bukstein OG, Walter HJ, Benson RS, Chrisman A, Farchione TR, Hamilton J, Keable H, Kinlan J, Schoettle U, Siegel M, Stock S, Ptakowski KK, Medicus J. Practice parameter for child and adolescent forensic evaluations. J Am Acad Child Adolesc Psychiatry. 2011 Dec; 50(12):1299-312. PMID: 22115153.
    Citations: 4     Fields:    Translation:Humans
  32. Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, Lyne A, Grannis K, Youcha S. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012 Jan; 51(1):74-85.e2. PMID: 22176941.
    Citations: 32     Fields:    Translation:Humans
  33. Farmer CA, Arnold LE, Bukstein OG, Findling RL, Gadow KD, Li X, Butter EM, Aman MG. The treatment of severe child aggression (TOSCA) study: Design challenges. Child Adolesc Psychiatry Ment Health. 2011 Nov 10; 5(1):36. PMID: 22074813.
    Citations: 18     
  34. Cornelius JR, Douaihy A, Bukstein OG, Daley DC, Wood SD, Kelly TM, Salloum IM. Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents. Addict Behav. 2011 Aug; 36(8):843-8. PMID: 21530092.
    Citations: 14     Fields:    Translation:Humans
  35. Demidovich M, Kolko DJ, Bukstein OG, Hart J. Medication refusal in children with oppositional defiant disorder or conduct disorder and comorbid attention-deficit/hyperactivity disorder: medication history and clinical correlates. J Child Adolesc Psychopharmacol. 2011 Feb; 21(1):57-66. PMID: 21288119.
    Citations: 6     Fields:    Translation:Humans
  36. Dorn LD, Kolko DJ, Shenk CE, Susman EJ, Bukstein O. Influence of treatment for disruptive behavior disorders on adrenal and gonadal hormones in youth. J Clin Child Adolesc Psychol. 2011; 40(4):562-71. PMID: 21722028.
    Citations: 4     Fields:    Translation:Humans
  37. Bukstein OG. Clinical practice guidelines for attention-deficit/hyperactivity disorder: a review. Postgrad Med. 2010 Sep; 122(5):69-77. PMID: 20861590.
    Citations:    Fields:    Translation:Humans
  38. Bukstein OG, Horner MS. Management of the adolescent with substance use disorders and comorbid psychopathology. Child Adolesc Psychiatr Clin N Am. 2010 Jul; 19(3):609-23. PMID: 20682224.
    Citations: 8     Fields:    Translation:Humans
  39. Cornelius JR, Bukstein OG, Douaihy AB, Clark DB, Chung TA, Daley DC, Wood DS, Brown SJ. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend. 2010 Nov 01; 112(1-2):39-45. PMID: 20576364.
    Citations: 23     Fields:    Translation:Humans
  40. Cohen JA, Bukstein O, Walter H, Benson SR, Chrisman A, Farchione TR, Hamilton J, Keable H, Kinlan J, Schoettle U, Siegel M, Stock S, Medicus J. Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. J Am Acad Child Adolesc Psychiatry. 2010 Apr; 49(4):414-30. PMID: 20410735.
    Citations: 54     Fields:    Translation:Humans
  41. Arnold LE, Bozzolo DR, Hodgkins P, McKay M, Beckett-Thurman L, Greenbaum M, Bukstein O, Patel A. Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Curr Med Res Opin. 2010 Jan; 26(1):129-37. PMID: 19916704.
    Citations: 5     Fields:    Translation:Humans
  42. Bukstein OG, Arnold LE, Landgraf JM, Hodgkins P. Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder? Child Adolesc Psychiatry Ment Health. 2009 Dec 10; 3(1):39. PMID: 20003260.
    Citations: 7     
  43. Goldstein BI, Bukstein OG. Comorbid substance use disorders among youth with bipolar disorder: opportunities for early identification and prevention. J Clin Psychiatry. 2010 Mar; 71(3):348-58. PMID: 19961811.
    Citations: 15     Fields:    Translation:Humans
  44. Cannon M, Pelham WH, Sallee FR, Palumbo DR, Bukstein O, Daviss WB. Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009 Oct; 19(5):511-7. PMID: 19877975.
    Citations: 9     Fields:    Translation:Humans
  45. Brent DA, Greenhill LL, Compton S, Emslie G, Wells K, Walkup JT, Vitiello B, Bukstein O, Stanley B, Posner K, Kennard BD, Cwik MF, Wagner A, Coffey B, March JS, Riddle M, Goldstein T, Curry J, Barnett S, Capasso L, Zelazny J, Hughes J, Shen S, Gugga SS, Turner JB. The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry. 2009 Oct; 48(10):987-996. PMID: 19730274.
    Citations: 40     Fields:    Translation:HumansPHPublic Health
  46. Vitiello B, Brent DA, Greenhill LL, Emslie G, Wells K, Walkup JT, Stanley B, Bukstein O, Kennard BD, Compton S, Coffey B, Cwik MF, Posner K, Wagner A, March JS, Riddle M, Goldstein T, Curry J, Capasso L, Mayes T, Shen S, Gugga SS, Turner JB, Barnett S, Zelazny J. Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. J Am Acad Child Adolesc Psychiatry. 2009 Oct; 48(10):997-1004. PMID: 20854770.
    Citations: 9     Fields:    Translation:HumansPHPublic Health
  47. Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, Civil R. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Ther. 2009 Aug; 31(8):1844-55. PMID: 19808143.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  48. Bukstein O. Substance use disorders and ADHD. CNS Spectr. 2009 Jul; 14(7 Suppl 6):10-1; discussion 13-4. PMID: 19802904.
    Citations:    Fields:    Translation:Humans
  49. Kolko DJ, Dorn LD, Bukstein OG, Pardini D, Holden EA, Hart J. Community vs. clinic-based modular treatment of children with early-onset ODD or CD: a clinical trial with 3-year follow-up. J Abnorm Child Psychol. 2009 Jul; 37(5):591-609. PMID: 19221871.
    Citations: 36     Fields:    Translation:Humans
  50. Bukstein OG. Transdermal methylphenidate system: old wine in a new bottle. Expert Opin Drug Metab Toxicol. 2009 Jun; 5(6):661-5. PMID: 19442029.
    Citations: 1     Fields:    Translation:Humans
  51. Kelly TM, Donovan JE, Chung T, Bukstein OG, Cornelius JR. Brief screens for detecting alcohol use disorder among 18-20 year old young adults in emergency departments: Comparing AUDIT-C, CRAFFT, RAPS4-QF, FAST, RUFT-Cut, and DSM-IV 2-Item Scale. Addict Behav. 2009 Aug; 34(8):668-74. PMID: 19398161.
    Citations: 20     Fields:    Translation:Humans
  52. Cornelius JR, Bukstein OG, Wood DS, Kirisci L, Douaihy A, Clark DB. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. Addict Behav. 2009 Oct; 34(10):905-9. PMID: 19321268.
    Citations: 20     Fields:    Translation:Humans
  53. DeMaso DR, Martini DR, Cahen LA, Bukstein O, Walter HJ, Benson S, Chrisman A, Farchione T, Hamilton J, Keable H, Kinlan J, Schoettle U, Siegel M, Stock S, Ptakowski KK, Medicus J. Practice parameter for the psychiatric assessment and management of physically ill children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009 Feb; 48(2):213-33. PMID: 20040826.
    Citations: 6     Fields:    Translation:Humans
  54. Dorn LD, Kolko DJ, Susman EJ, Huang B, Stein H, Music E, Bukstein OG. Salivary gonadal and adrenal hormone differences in boys and girls with and without disruptive behavior disorders: Contextual variants. Biol Psychol. 2009 Apr; 81(1):31-9. PMID: 19428966.
    Citations: 18     Fields:    Translation:Humans
  55. Stanley JA, Kipp H, Greisenegger E, MacMaster FP, Panchalingam K, Keshavan MS, Bukstein OG, Pettegrew JW. Evidence of developmental alterations in cortical and subcortical regions of children with attention-deficit/hyperactivity disorder: a multivoxel in vivo phosphorus 31 spectroscopy study. Arch Gen Psychiatry. 2008 Dec; 65(12):1419-28. PMID: 19047529.
    Citations: 6     Fields:    Translation:Humans
  56. Bukstein O. Substance use disorders in adolescents with attention-deficit/hyperactivity disorder. Adolesc Med State Art Rev. 2008 Aug; 19(2):242-53, viii. PMID: 18822830.
    Citations: 6     Fields:    Translation:HumansPHPublic Health
  57. Faraone SV, Glatt SJ, Bukstein OG, Lopez FA, Arnold LE, Findling RL. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord. 2009 Jan; 12(4):308-15. PMID: 18400982.
    Citations: 12     Fields:    Translation:Humans
  58. Marshal MP, Friedman MS, Stall R, King KM, Miles J, Gold MA, Bukstein OG, Morse JQ. Sexual orientation and adolescent substance use: a meta-analysis and methodological review. Addiction. 2008 Apr; 103(4):546-56. PMID: 18339100.
    Citations: 165     Fields:    Translation:Humans
  59. Szobot CM, Bukstein O. Attention deficit hyperactivity disorder and substance use disorders. Child Adolesc Psychiatr Clin N Am. 2008 Apr; 17(2):309-23, viii. PMID: 18295148.
    Citations: 7     Fields:    Translation:Humans
  60. Szobot CM, Rohde LA, Katz B, Ruaro P, Schaefer T, Walcher M, Bukstein O, Pechansky F. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. Braz J Med Biol Res. 2008 Mar; 41(3):250-7. PMID: 18327433.
    Citations: 7     Fields:    Translation:Humans
  61. Palumbo DR, Sallee FR, Pelham WE, Bukstein OG, Daviss WB, McDERMOTT MP. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008 Feb; 47(2):180-188. PMID: 18182963.
    Citations: 32     Fields:    Translation:Humans
  62. Daviss WB, Patel NC, Robb AS, McDERMOTT MP, Bukstein OG, Pelham WE, Palumbo D, Harris P, Sallee FR. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry. 2008 Feb; 47(2):189-198. PMID: 18182964.
    Citations: 25     Fields:    Translation:Humans
  63. Bukstein O. Substance abuse in patients with attention-deficit/hyperactivity disorder. Medscape J Med. 2008 Jan 31; 10(1):24. PMID: 18324334.
    Citations: 5     Fields:    Translation:HumansPHPublic Health
  64. Molina BS, Flory K, Bukstein OG, Greiner AR, Baker JL, Krug V, Evans SW. Feasibility and preliminary efficacy of an after-school program for middle schoolers with ADHD: a randomized trial in a large public middle school. J Atten Disord. 2008 Nov; 12(3):207-17. PMID: 18192624.
    Citations: 5     Fields:    Translation:Humans
  65. Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008 Jan; 69(1):149-59. PMID: 18312050.
    Citations: 19     Fields:    Translation:Humans
  66. Birmaher B, Brent D, Bernet W, Bukstein O, Walter H, Benson RS, Chrisman A, Farchione T, Greenhill L, Hamilton J, Keable H, Kinlan J, Schoettle U, Stock S, Ptakowski KK, Medicus J. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007 Nov; 46(11):1503-26. PMID: 18049300.
    Citations: 154     Fields:    Translation:Humans
  67. Manos MJ, Tom-Revzon C, Bukstein OG, Crismon ML. Changes and challenges: managing ADHD in a fast-paced world. J Manag Care Pharm. 2007 Nov; 13(9 Suppl B):S2-S13; quiz S14-S16. PMID: 18062734.
    Citations: 7     Fields:    Translation:Humans
  68. March JS, Szatmari P, Bukstein O, Chrisman A, Kondo D, Hamilton JD, Kremer CME, Kratochvil CJ. AACAP 2005 Research Forum: speeding the adoption of evidence-based practice in pediatric psychiatry. J Am Acad Child Adolesc Psychiatry. 2007 Sep; 46(9):1098-1110. PMID: 17712233.
    Citations: 2     Fields:    Translation:Humans
  69. Szobot CM, Rohde LA, Bukstein O, Molina BS, Martins C, Ruaro P, Pechansky F. Is attention-deficit/hyperactivity disorder associated with illicit substance use disorders in male adolescents? A community-based case-control study. Addiction. 2007 Jul; 102(7):1122-30. PMID: 17567400.
    Citations: 16     Fields:    Translation:Humans
  70. Stanley JA, Kipp H, Greisenegger E, MacMaster FP, Panchalingam K, Pettegrew JW, Keshavan MS, Bukstein OG. Regionally specific alterations in membrane phospholipids in children with ADHD: An in vivo 31P spectroscopy study. Psychiatry Res. 2006 Dec 01; 148(2-3):217-21. PMID: 17095197.
    Citations: 8     Fields:    Translation:HumansCells
  71. McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, Stein M. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2006 Jun; 16(3):351-6. PMID: 16768642.
    Citations: 10     Fields:    Translation:Humans
  72. Bukstein OG. Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders. Expert Rev Neurother. 2006 Apr; 6(4):541-9. PMID: 16623653.
    Citations: 2     Fields:    Translation:Humans
  73. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2006 Jan; 160(1):82-90. PMID: 16389216.
    Citations: 33     Fields:    Translation:HumansCells
  74. Bukstein OG, Cornelius J, Trunzo AC, Kelly TM, Wood DS. Clinical predictors of treatment in a population of adolescents with alcohol use disorders. Addict Behav. 2005 Oct; 30(9):1663-73. PMID: 16165305.
    Citations: 3     Fields:    Translation:Humans
  75. Kelly TM, Donovan JE, Cornelius JR, Bukstein OG, Delbridge TR, Kinnane JM. Alcohol use disorder symptoms and risk-taking behavior as predictors of alcohol-related medical events among young adults treated in emergency departments. Addict Behav. 2005 Oct; 30(9):1674-89. PMID: 16099594.
    Citations: 5     Fields:    Translation:HumansPHPublic Health
  76. Cornelius JR, Clark DB, Bukstein OG, Birmaher B, Salloum IM, Brown SA. Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review. Addict Behav. 2005 Oct; 30(9):1824-33. PMID: 16102905.
    Citations: 16     Fields:    Translation:Humans
  77. Bukstein OG, Bernet W, Arnold V, Beitchman J, Shaw J, Benson RS, Kinlan J, McClellan J, Stock S, Ptakowski KK. Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. J Am Acad Child Adolesc Psychiatry. 2005 Jun; 44(6):609-21. PMID: 15908844.
    Citations: 27     Fields:    Translation:HumansPHPublic Health
  78. Cornelius JR, Clark DB, Bukstein OG, Kelly TM, Salloum IM, Wood DS. Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder: a 3-year follow-up study. Addict Behav. 2005 May; 30(4):807-14. PMID: 15833583.
    Citations: 2     Fields:    Translation:Humans
  79. Chacko A, Pelham WE, Gnagy EM, Greiner A, Vallano G, Bukstein O, Rancurello M. Stimulant medication effects in a summer treatment program among young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2005 Mar; 44(3):249-57. PMID: 15725969.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  80. Bukstein OG, Trunzo AC. Alcohol use disorder in adolescents. Minerva Pediatr. 2005 Feb; 57(1):7-20. PMID: 15791198.
    Citations:    Fields:    Translation:Humans
  81. Cornelius JR, Clark DB, Bukstein OG, Salloum IM. Treatment of co-occurring alcohol, drug, and psychiatric disorders. Recent Dev Alcohol. 2005; 17:349-65. PMID: 15789875.
    Citations: 5     Fields:    Translation:Humans
  82. Fritz G, Rockney R, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S, Kroeger Ptakowski K. Practice parameter for the assessment and treatment of children and adolescents with enuresis. J Am Acad Child Adolesc Psychiatry. 2004 Dec; 43(12):1540-50. PMID: 15564822.
    Citations: 10     Fields:    Translation:Humans
  83. Ghaziuddin N, Kutcher SP, Knapp P, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S, Kroeger Ptakowski K. Practice parameter for use of electroconvulsive therapy with adolescents. J Am Acad Child Adolesc Psychiatry. 2004 Dec; 43(12):1521-39. PMID: 15564821.
    Citations: 14     Fields:    Translation:Humans
  84. Bukstein OG, Winters K. Salient variables for treatment research of adolescent alcohol and other substance use disorders. Addiction. 2004 Nov; 99 Suppl 2:23-37. PMID: 15488103.
    Citations: 3     Fields:    Translation:Humans
  85. Cornelius JR, Maisto SA, Martin CS, Bukstein OG, Salloum IM, Daley DC, Wood DS, Clark DB. Major depression associated with earlier alcohol relapse in treated teens with AUD. Addict Behav. 2004 Jul; 29(5):1035-8. PMID: 15219354.
    Citations: 25     Fields:    Translation:Humans
  86. Bukstein OG. Satisfaction with treatment for attention-deficit/hyperactivity disorder. Am J Manag Care. 2004 Jul; 10(4 Suppl):S107-16. PMID: 15352537.
    Citations: 9     Fields:    Translation:Humans
  87. Cornelius JR, Clark DB, Salloum IM, Bukstein OG, Kelly TM. Interventions in suicidal alcoholics. Alcohol Clin Exp Res. 2004 May; 28(5 Suppl):89S-96S. PMID: 15166640.
    Citations: 11     Fields:    Translation:Humans
  88. Cornelius JR, Bukstein OG, Salloum IM, Kelly TM, Wood DS, Clark DB. Fluoxetine in depressed AUD adolescents: a 1-year follow-up evaluation. J Child Adolesc Psychopharmacol. 2004; 14(1):33-8. PMID: 15142389.
    Citations: 7     Fields:    Translation:Humans
  89. Clark DB, Wood DS, Cornelius JR, Bukstein OG, Martin CS. Clinical practices in the pharmacological treatment of comorbid psychopathology in adolescents with alcohol use disorders. J Subst Abuse Treat. 2003 Dec; 25(4):293-5. PMID: 14693259.
    Citations: 4     Fields:    Translation:Humans
  90. Kelly TM, Donovan JE, Cornelius JR, Bukstein OG, Delbridge TR, Clark DB. Psychiatric disorders among older adolescents treated in emergency departments on weekends: a comparison with a matched community sample. J Stud Alcohol. 2003 Sep; 64(5):616-22. PMID: 14572182.
    Citations: 3     Fields:    Translation:Humans
  91. Bukstein OG. Once-daily atomoxetine may reduce attention deficit hyperactivity disorder symptoms in children and adolescents. Evid Based Ment Health. 2003 May; 6(2):42. PMID: 12719349.
    Citations:    Fields:    
  92. Cornelius JR, Bukstein O, Salloum I, Clark D. Alcohol and psychiatric comorbidity. Recent Dev Alcohol. 2003; 16:361-74. PMID: 12638646.
    Citations: 17     Fields:    Translation:Humans
  93. Molina BS, Bukstein OG, Lynch KG. Attention-deficit/hyperactivity disorder and conduct disorder symptomatology in adolescents with alcohol use disorder. Psychol Addict Behav. 2002 Jun; 16(2):161-4. PMID: 12079256.
    Citations: 18     Fields:    Translation:Humans
  94. Masters KJ, Bellonci C, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S. Practice parameter for the prevention and management of aggressive behavior in child and adolescent psychiatric institutions, with special reference to seclusion and restraint. J Am Acad Child Adolesc Psychiatry. 2002 Feb; 41(2 Suppl):4S-25S. PMID: 11833634.
    Citations: 19     Fields:    Translation:Humans
  95. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002 Feb; 41(2 Suppl):26S-49S. PMID: 11833633.
    Citations: 144     Fields:    Translation:Humans
  96. Clark DB, Bukstein O, Cornelius J. Alcohol use disorders in adolescents: epidemiology, diagnosis, psychosocial interventions, and pharmacological treatment. Paediatr Drugs. 2002; 4(8):493-502. PMID: 12126453.
    Citations: 11     Fields:    Translation:Humans
  97. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S, Kroeger K. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2001 Nov; 40(11):1352-5. PMID: 11699811.
    Citations: 17     Fields:    Translation:Humans
  98. Masters KJ, Bellonci C, Bernet W, Arnold V, Beitchman J, Benson S, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S, Kroeger K. Summary of the practice parameter for the prevention and management of aggressive behavior in child and adolescent psychiatric institutions with special reference to seclusion and restraint. J Am Acad Child Adolesc Psychiatry. 2001 Nov; 40(11):1356-8. PMID: 11699812.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  99. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001 Oct; 108(4):883-92. PMID: 11581440.
    Citations: 78     Fields:    Translation:HumansCTClinical Trials
  100. Cornelius JR, Bukstein OG, Birmaher B, Salloum IM, Lynch K, Pollock NK, Gershon S, Clark D. Fluoxetine in adolescents with major depression and an alcohol use disorder: an open-label trial. Addict Behav. 2001 Sep-Oct; 26(5):735-9. PMID: 11676382.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  101. Evans SW, Pelham WE, Smith BH, Bukstein O, Gnagy EM, Greiner AR, Altenderfer L, Baron-Myak C. Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Exp Clin Psychopharmacol. 2001 May; 9(2):163-75. PMID: 11518092.
    Citations: 32     Fields:    Translation:HumansCTClinical Trials
  102. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Wells K, Wigal T. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001 Feb; 40(2):180-7. PMID: 11211366.
    Citations: 51     Fields:    Translation:HumansCTClinical Trials
  103. Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, Elliott GR, Hechtman L, Jensen PS, Hinshaw SP, March JS, Newcorn JH, Swanson JM, Cantwell DP. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry. 2001 Feb; 40(2):188-96. PMID: 11211367.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  104. Pelham WE, Gnagy EM, Greiner AR, Hoza B, Hinshaw SP, Swanson JM, Simpson S, Shapiro C, Bukstein O, Baron-Myak C, McBurnett K. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. J Abnorm Child Psychol. 2000 Dec; 28(6):507-25. PMID: 11104314.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  105. Martin CS, Pollock NK, Bukstein OG, Lynch KG. Inter-rater reliability of the SCID alcohol and substance use disorders section among adolescents. Drug Alcohol Depend. 2000 May 01; 59(2):173-6. PMID: 10891630.
    Citations: 56     Fields:    Translation:Humans
  106. Bukstein OG. Disruptive behavior disorders and substance use disorders in adolescents. J Psychoactive Drugs. 2000 Jan-Mar; 32(1):67-79. PMID: 10801069.
    Citations: 4     Fields:    Translation:Humans
  107. Kolko DJ, Bukstein OG, Barron J. Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. J Am Acad Child Adolesc Psychiatry. 1999 May; 38(5):578-86. PMID: 10230190.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  108. Bukstein OG, Kolko DJ. Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder. J Clin Child Psychol. 1998 Oct; 27(3):340-51. PMID: 9789193.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  109. Smith BH, Pelham WE, Evans S, Gnagy E, Molina B, Bukstein O, Greiner A, Myak C, Presnell M, Willoughby M. Dosage effects of methylphenidate on the social behavior of adolescents diagnosed with attention-deficit hyperactivity disorder. Exp Clin Psychopharmacol. 1998 May; 6(2):187-204. PMID: 9608351.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  110. Clark DB, Bukstein OG. Psychopathology in adolescent alcohol abuse and dependence. Alcohol Health Res World. 1998; 22(2):117-21, 126. PMID: 15706785.
    Citations: 15     Fields:    Translation:Humans
  111. Bukstein O. Practice parameters for the assessment and treatment of children and adolescents with substance use disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997 Oct; 36(10 Suppl):140S-56S. PMID: 9334569.
    Citations: 7     Fields:    Translation:Humans
  112. Clark DB, Pollock N, Bukstein OG, Mezzich AC, Bromberger JT, Donovan JE. Gender and comorbid psychopathology in adolescents with alcohol dependence. J Am Acad Child Adolesc Psychiatry. 1997 Sep; 36(9):1195-203. PMID: 9291720.
    Citations: 47     Fields:    Translation:Humans
  113. Clark DB, Bukstein OG, Smith MG, Kaczynski NA, Mezzich AC, Donovan JE. Identifying anxiety disorders in adolescents hospitalized for alcohol abuse or dependence. Psychiatr Serv. 1995 Jun; 46(6):618-20. PMID: 7641008.
    Citations: 12     Fields:    Translation:Humans
  114. Arria AM, Dohey MA, Mezzich AC, Bukstein OG, Van Thiel DH. Self-reported health problems and physical symptomatology in adolescent alcohol abusers. J Adolesc Health. 1995 Mar; 16(3):226-31. PMID: 7779833.
    Citations: 10     Fields:    Translation:Humans
  115. Messer SC, Kempton T, Van Hasselt VB, Null JA, Bukstein OG. Cognitive distortions and adolescent affective disorder. Validity of the CNCEQ in an inpatient sample. Children's Negative Cognitive Error Questionnaire. Behav Modif. 1994 Jul; 18(3):339-51. PMID: 8037653.
    Citations: 4     Fields:    Translation:Humans
  116. Leonard HL, Topol D, Bukstein O, Hindmarsh D, Allen AJ, Swedo SE. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1994 Jul-Aug; 33(6):792-4. PMID: 8083135.
    Citations: 4     Fields:    Translation:Humans
  117. Kempton T, van Hasselt VB, Bukstein OG, Null JA. Cognitive distortions and psychiatric diagnosis in dually diagnosed adolescents. J Am Acad Child Adolesc Psychiatry. 1994 Feb; 33(2):217-22. PMID: 8150793.
    Citations: 2     Fields:    Translation:Humans
  118. Bukstein OG. Treatment of Adolescent Alcohol Abuse and Dependence. Alcohol Health Res World. 1994; 18(4):296-301. PMID: 31798037.
    Citations:    
  119. Bukstein OG, Brent DA, Perper JA, Moritz G, Baugher M, Schweers J, Roth C, Balach L. Risk factors for completed suicide among adolescents with a lifetime history of substance abuse: a case-control study. Acta Psychiatr Scand. 1993 Dec; 88(6):403-8. PMID: 8310846.
    Citations: 21     Fields:    Translation:Humans
  120. Van Hasselt VB, Hersen M, Null JA, Ammerman RT, Bukstein OG, McGillivray J, Hunter A. Drug abuse prevention for high-risk African American children and their families: a review and model program. Addict Behav. 1993 Mar-Apr; 18(2):213-34. PMID: 8506792.
    Citations: 1     Fields:    Translation:Humans
  121. Van Hasselt VB, Null JA, Kempton T, Bukstein OG. Social skills and depression in adolescent substance abusers. Addict Behav. 1993 Jan-Feb; 18(1):9-18. PMID: 8465682.
    Citations: 3     Fields:    Translation:Humans
  122. Martin CS, Arria AM, Mezzich AC, Bukstein OG. Patterns of polydrug use in adolescent alcohol abusers. Am J Drug Alcohol Abuse. 1993; 19(4):511-21. PMID: 8273771.
    Citations: 6     Fields:    Translation:Humans
  123. Kaminer Y, Tarter RE, Bukstein OG, Kabene M. Comparison between treatment completers and noncompleters among dually diagnosed substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry. 1992 Nov; 31(6):1046-9. PMID: 1429403.
    Citations: 10     Fields:    Translation:Humans
  124. Bukstein OG, Glancy LJ, Kaminer Y. Patterns of affective comorbidity in a clinical population of dually diagnosed adolescent substance abusers. J Am Acad Child Adolesc Psychiatry. 1992 Nov; 31(6):1041-5. PMID: 1429402.
    Citations: 33     Fields:    Translation:Humans
  125. Van Hasselt VB, Ammerman RT, Glancy LJ, Bukstein OG. Maltreatment in psychiatrically hospitalized dually diagnosed adolescent substance abusers. J Am Acad Child Adolesc Psychiatry. 1992 Sep; 31(5):868-74. PMID: 1400119.
    Citations: 2     Fields:    Translation:Humans
  126. Kaminer Y, Bukstein O, Tarter RE. The Teen-Addiction Severity Index: rationale and reliability. Int J Addict. 1991 Feb; 26(2):219-26. PMID: 1889921.
    Citations: 18     Fields:    Translation:Humans
  127. Tarter RE, Laird S, Bukstein O. Multivariate comparison of adolescent offspring of substance abuse parents: community and treatment samples. J Subst Abuse. 1991; 3(3):301-6. PMID: 1821286.
    Citations:    Fields:    Translation:Humans
  128. Tarter RE, Laird SB, Kabene M, Bukstein O, Kaminer Y. Drug abuse severity in adolescents is associated with magnitude of deviation in temperament traits. Br J Addict. 1990 Nov; 85(11):1501-4. PMID: 2285849.
    Citations: 8     Fields:    Translation:Humans
  129. Brent DA, Zelenak JP, Bukstein O, Brown RV. Reliability and validity of the structured interview for personality disorders in adolescents. J Am Acad Child Adolesc Psychiatry. 1990 May; 29(3):349-54. PMID: 2347829.
    Citations: 5     Fields:    Translation:Humans
  130. Bukstein OG, Brent DA, Kaminer Y. Comorbidity of substance abuse and other psychiatric disorders in adolescents. Am J Psychiatry. 1989 Sep; 146(9):1131-41. PMID: 2669535.
    Citations: 40     Fields:    Translation:Humans
  131. Kaminer Y, Bukstein O. Adolescent chemical use and dependence: current issues in epidemiology, treatment and prevention. Acta Psychiatr Scand. 1989 May; 79(5):415-24. PMID: 2665421.
    Citations: 1     Fields:    Translation:Humans
  132. Kaminer Y, Bukstein O, Tarter R. Teen Addiction Severity Index (T-ASI): clinical and research implications: a preliminary report. NIDA Res Monogr. 1989; 95:363. PMID: 2640997.
    Citations: 1     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Bukstein's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (310)
Explore
_
Co-Authors (8)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.